Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HMGCR | P04035 | 1/20 | 0.61 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.61 |
| ▸ | NFE2L2 | Q16236 | 2/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.52 |
| ▸ | TSHR | P16473 | 2/20 | 0.52 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.52 |
| ▸ | CYP1A1 | P04798 | 5/20 | 0.52 |
| ▸ | CYP1B1 | Q16678 | 5/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 4/20 | 0.52 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 2/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.44 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.44 |
| ▸ | NOD2 | Q9HC29 | 1/20 | 0.40 |
| ▸ | APP | P05067 | 1/20 | 0.39 |
| ▸ | SNCA | P37840 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19369822 | 0.84 | HMGCR (0.57) | HMGCRCYP3A4NFE2L2KDM4EALDH1A1 | |
| Acoramol SCHEMBL10948421 | 0.82 | HMGCR (0.59) | HMGCRCYP3A4NFE2L2KDM4EALDH1A1 | |
| Acoramol SCHEMBL10948411 | 0.82 | HMGCR (0.59) | HMGCRCYP3A4NFE2L2KDM4EALDH1A1 | |
| SCHEMBL19361701 | 0.79 | HMGCR (0.55) | HMGCRCYP3A4NFE2L2KDM4EALDH1A1 | |
| SCHEMBL30758000 | 0.77 | CYP1A1 (0.64) | NFE2L2KDM4ETDP1CYP1A1CYP1B1 | |
| SCHEMBL12521534 | 0.77 | CYP1A1 (0.64) | NFE2L2KDM4ETDP1CYP1A1CYP1B1 | |
| SCHEMBL14416280 | 0.77 | CYP1A1 (0.64) | NFE2L2KDM4ETDP1CYP1A1CYP1B1 | |
| SCHEMBL29565899 | 0.76 | CYP1A2 (0.46) | CYP3A4NFE2L2KDM4EALDH1A1TSHR | |
| SCHEMBL19416167 | 0.76 | ALDH1A1 (0.53) | HMGCRCYP3A4NFE2L2KDM4EALDH1A1 | |
| SCHEMBL10050048 | 0.76 | MAPT (0.51) | CYP3A4KDM4EALDH1A1TSHRCYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3225627-A1 | TRIPEPTIDE COMPOUND, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF | Northwest University (CN) | 2017-10-04 | — | — | EP | disclosed |
| US-20170267718-A1 | TRIPEPTIDE COMPOUND, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF | NORTHWEST UNIVERSITY (CN) | 2017-09-21 | — | — | US | disclosed |
| US-20170267718-A1 | TRIPEPTIDE COMPOUND, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF | NORTHWEST UNIVERSITY (CN) | 2017-09-21 | — | — | US | disclosed |
| US-20170260122-A1 | a-ASARY-LALDEHYDE ESTER, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF | NORTHWEST UNIVERSITY (CN) | 2017-09-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170260122-A1 | a-ASARY-LALDEHYDE ESTER, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF | LSS, CYP51A1, BACE1 | HMGCR 225/4885CYP3A4 303/4885NFE2L2 1640/4885 |
| US-20170267718-A1 | TRIPEPTIDE COMPOUND, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF | VIP, PREP, ACE | HMGCR 559/4885CYP3A4 2295/4885NFE2L2 2308/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.